Ossiam Sells 997 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ossiam lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,173 shares of the biopharmaceutical company's stock after selling 997 shares during the period. Ossiam's holdings in Regeneron Pharmaceuticals were worth $11,521,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Capital International Investors increased its stake in Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares during the period. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $802,036,000. Amundi raised its stake in Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after acquiring an additional 487,489 shares in the last quarter. Loomis Sayles & Co. L P increased its position in shares of Regeneron Pharmaceuticals by 33.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock worth $1,122,168,000 after purchasing an additional 393,997 shares in the last quarter. Finally, Proficio Capital Partners LLC increased its holdings in shares of Regeneron Pharmaceuticals by 92,865.3% during the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock worth $156,284,000 after buying an additional 219,162 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on REGN. Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research note on Monday, January 27th. The Goldman Sachs Group cut their price objective on shares of Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Bank of America decreased their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. Citigroup cut their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Finally, Robert W. Baird dropped their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $949.60.

Regeneron Pharmaceuticals Stock Up 1.1 %

NASDAQ REGN traded up $6.46 on Thursday, hitting $594.31. 591,943 shares of the company were exchanged, compared to its average volume of 718,038. Regeneron Pharmaceuticals, Inc. has a 12 month low of $525.99 and a 12 month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a market cap of $64.97 billion, a PE ratio of 15.55, a PEG ratio of 2.34 and a beta of 0.44. The stock has a fifty day moving average of $640.41 and a 200-day moving average of $731.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $11.86 EPS. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.